Gastrointestinal Motility Disorder Clinical Trial
Official title:
Gastrointestinal Motor Disorders (Esophageal and Anorectal) in Patients After COVID-19 Infection
The patients who had COVID-19 infection, and after that reported for one of the signs of gastrointestinal disorder (esophageal and anorectal) will be underwent to esophageal and anorectal motor monitoring investigation (HRM manometry) on standard protocol.
| Status | Recruiting |
| Enrollment | 120 |
| Est. completion date | August 31, 2023 |
| Est. primary completion date | September 30, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 20 Years to 80 Years |
| Eligibility | Inclusion Criteria: - Patients with esophageal and anorectal symptoms after COVID 19- infection - Patients with worsening of esophageal and anorectal symptom after COVID 19- infection, but who had previously described esophageal and anorectal symptoms Exclusion Criteria: - Other gastrointestinal disease that can influence to results - Gastroesophageal reflux - H. Pylori infection - Bacterial, parasitic, viral and fungal gastrointestinal infection or infestation - Myasthenia - Scleroderma - Diabetes mellitus - Thyroidal hyperfunction |
| Country | Name | City | State |
|---|---|---|---|
| Croatia | Prof.dr.sc. Žarko Babic, FEBGH | Zagreb | Select State |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital Dubrava |
Croatia,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Measurement of esophageal parameters 1 on manometry | In esophagus we will measure Upper and lower esophageal sphincter pressure in mmHg. | 120 days | |
| Primary | Measurement of esophageal parameters 2 on manometry | In esophagus we will measure Integrated relaxation pressure (IRP) in mmHg. | 120 days | |
| Primary | Measurement of esophageal parameters 3 on manometry | In esophagus we will measure Contractile front velocity (CVF) in cm/s. | 120 days | |
| Primary | Measurement of esophageal parameters 4 on manometry | In esophagus we will measure Distal contractile integral (DCI) in mmHg.s.cm. | 120 days | |
| Primary | Measurement of esophageal parameters 5 on manometry | In esophagus we will measure Distal latency (DL) in seconds. | 120 days | |
| Primary | Measurement of esophageal parameters 6 on manometry | In esophagus we will measure Peristaltic brake (BR) in cm. | 120 days | |
| Primary | Measurement of anorectal parameters 1 on manometry | On anorectal manometry we will measure Resting test pressure in mmHg. | 2 years | |
| Primary | Measurement of anorectal parameters 2 on manometry | On anorectal manometry we will measure Squeeze test pressure in mmHg. | 2 years | |
| Primary | Measurement of anorectal parameters 3 on manometry | On anorectal manometry we will measure Endurance squeeze test pressure in mmHg. | 2 years | |
| Primary | Measurement of anorectal parameters 4 on manometry | On anorectal manometry we will measure recto-anal inhibitory reflex test (RAIR)- relaxation in percent. | 2 years | |
| Primary | Measurement of anorectal parameters 5 on manometry | On anorectal manometry we will measure Push test pressure in mmHg. | 2 years | |
| Primary | Measurement of anorectal parameters 6 on manometry | On anorectal manometry we will measure Sensation test with ml in balloon. | 2 years | |
| Primary | Measurement of anorectal parameters 7 on manometry | On anorectal manometry we will measure Balloon expulsion test as positive or negative. | 2 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04429802 -
The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity
|
N/A | |
| Completed |
NCT01644240 -
A Phase 1, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
|
Phase 1 | |
| Withdrawn |
NCT04244877 -
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
|
Phase 3 | |
| Terminated |
NCT02573519 -
Gastrointestinal Motility Among Diabetes Patients
|
N/A | |
| Recruiting |
NCT04764019 -
Intestinal Dysmotility in Patients With Functional Digestive Symptoms
|
N/A | |
| Completed |
NCT03012594 -
Lanreotide in the Treatment of Small Bowel Motility Disorders
|
Phase 2 | |
| Not yet recruiting |
NCT05268328 -
The Effect of Foot Reflexology After Cesarean Section
|
||
| Completed |
NCT02245165 -
Nitric Oxide Control of Migrating Motor Complex: L-NMMA Effects in Relation to Receptor Blockades
|
Phase 1 | |
| Completed |
NCT03552510 -
Oropharyngeal Administration of Mother's Milk in Preterm Infants and Gastrointestinal Motility
|
N/A | |
| Completed |
NCT01394055 -
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
|
Phase 1 | |
| Active, not recruiting |
NCT00793195 -
Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?
|
Phase 2 | |
| Recruiting |
NCT04208828 -
IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
|
||
| Active, not recruiting |
NCT06347367 -
Short-term Effect of Exercise and Self-manual Approaches to Bloating - Distention
|
N/A | |
| Recruiting |
NCT05989763 -
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
|
N/A | |
| Completed |
NCT01635608 -
Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water
|
Phase 1 |